BridgeBio Oncology Therapeutics Inc Dossier - Source-backed chat

BridgeBio Oncology Therapeutics Inc

BBOTNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.91

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $3.94Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $315.9M

Enterprise Value −$73M

Shares Outstanding 80M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

BridgeBio Oncology Therapeutics (BBOT) represents a high-conviction, clinical-stage precision oncology play targeting the highly lucrative but historically challenging RAS and PI3Kα pathways. Spun out of BridgeBio Pharma in 2024 and subsequently taken public, BBOT is uniquely positioned with three clinical-stage assets (BBO-8520, BBO-11818, and BBO-10203) that address the limitations of first-generation inhibitors. By targeting both the active 'ON' and inactive 'OFF' states of KRAS, and blocking the physical interaction between RAS and PI3Kα without inducing hyperglycemia, BBOT's pipeline offers best-in-class potential. Backed by a strong cash runway extending into 2028 and led by newly appointed CEO Dr. Pedro Beltran, the company is poised for a catalyst-rich second half of 2026 as combination data readouts emerge.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets10 analysts · as of 18 Aug 2026

Low · most bearish analyst$18.00

Mean target$25.30

High · most bullish analyst$41.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

Dose-limiting toxicities emerge in the pan-KRAS (BBO-11818) expansion cohorts, or the combination of BBO-8520 with pembrolizumab shows cumulative liver toxicity that limits its therapeutic window. Additionally, internal combinations with BBO-10203 prove too toxic for continuous dosing, undermining the company's dual-pathway inhibition strategy. BBOT is forced to downsize its pipeline, accelerating cash burn and depressing the stock toward its cash floor.

Base CaseCentral scenario

BBOT successfully advances its three core programs through Phase 1b expansion. BBO-8520 demonstrates superior durability and a differentiated liver safety profile in combination with pembrolizumab compared to first-generation G12C inhibitors. BBO-11818 establishes proof-of-concept as a viable pan-KRAS inhibitor in pancreatic and colorectal cancers. BBO-10203 continues to show zero hyperglycemia, enabling successful internal combinations with the KRAS assets. The stock rerates toward consensus targets as clinical risk is mitigated.

Bull CaseUpside scenario

BBOT possesses a highly differentiated, wholly owned precision oncology pipeline targeting the RAS and PI3Kα pathways (BBO-8520, BBO-11818, and BBO-10203). Early clinical data demonstrates strong efficacy (e.g., 65% ORR for BBO-8520 in KRASG12C NSCLC and confirmed PR in pancreatic cancer for BBO-11818) combined with a highly differentiated safety profile (no hyperglycemia observed for BBO-10203). This profile uniquely positions BBOT to execute safe, concurrent, high-level suppression of both pathways via internal combination regimens, supported by a robust cash runway extending into 2028.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Differentiated 'ON/OFF' targeting mechanism designed to overcome adaptive resistance seen in first-generation 'OFF'-only KRAS inhibitors.
BBO-10203 avoids the class-wide toxicity of hyperglycemia by blocking the physical RAS-PI3Kα interaction rather than catalytic activity, enabling safe combination regimens.
Strong financial backing with a cash runway extending into 2028, protecting the company from near-term dilutive financing pressures.
Robust preliminary clinical data, including a 65% ORR for BBO-8520 in NSCLC and the first clinically confirmed monotherapy pan-KRAS response in pancreatic cancer for BBO-11818.

Key Investment Risks

High clinical and execution risk inherent to early-stage (Phase 1/2) oncology drug development.
Intense competition in the KRAS and precision oncology space from well-capitalized pharmaceutical majors and established biotech players.
Potential for cumulative or unexpected toxicities to emerge as assets transition from monotherapy to combination cohorts.

Thesis Invalidation Triggers

Failure of BBO-8520 + pembrolizumab combination to show a differentiated liver safety profile or acceptable tolerability in the H2 2026 readout.
Emergence of severe, class-limiting toxicities in the BBO-11818 pan-KRAS dose expansion cohorts.
Inability to initiate or safely dose patients in the planned internal combination trials of BBO-10203 with the KRAS inhibitors.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.